Ascentage Pharma Group International is a biopharmaceutical company specializing in the research, development, and commercialization of innovative therapies for cancer, hepatitis, and age-related diseases. Known for its expertise in apoptosis-targeted drug discovery, Ascentage Pharma focuses on developing first-in-class or best-in-class therapies that address unmet medical needs. The company is deeply involved in advancing oncology therapeutics, with a robust portfolio of small-molecule drugs designed to inhibit or promote apoptosis in diseased cells. Its strategic operations span pre-clinical and clinical trials, aiming to bring novel treatments to market that significantly impact the oncology and age-related disease sectors. Ascentage Pharma plays a critical role in the pharmaceutical industry by pushing the boundaries of traditional therapeutic methods and contributing to the overall progress in life sciences and biotechnology. Listed in Hong Kong, the company has garnered attention for its collaborations and partnerships with researchers and academic institutions worldwide, emphasizing its commitment to global health improvements.